Tenofovir disoproxil
- Generic Name
- Tenofovir disoproxil
- Brand Names
- Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Truvada, Viread, Tenofovir disoproxil Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C19H30N5O10P
- CAS Number
- 201341-05-1
- Unique Ingredient Identifier
- F4YU4LON7I
- Background
Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 .
- Indication
Tenofovir disoproxil is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients ≥2 years old and weighing ≥10 kg. It is also indicated for the treatment of chronic hepatitis B in patients ≥2 years old and weighing ≥10 kg.
Tenofovir disoproxil is also an ingredient in several combination products, all of which are indicated either alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.
In addition, tenofovir disoproxil is available in combination with emtricitabine (under the brand name Truvada) for use as pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing ≥ 35kg to reduce the risk of sexually-acquired HIV-1 infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
- Conditions
- Hepatitis DHepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04847440
- Locations
- 🇲🇩
Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit, Chisinau, Republic Of Moldova, Moldova, Republic of
🇺🇦Medical Center of Limited Liability Company "Harmoniya krasy", Kyiv, Ukraine
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 475
- Registration Number
- NCT04846491
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Traditional Chinese Medicine hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
🇨🇳The First Hospital of Shanxi Medical University, Taiyuan, China
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 105711
- Registration Number
- NCT04798287
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 105711
- Registration Number
- NCT04772248
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Reducing Vertical Transmission of Hepatitis B in Africa
- Conditions
- Hepatitis B Infection
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 450
- Registration Number
- NCT04704024
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04667104
- Locations
- 🇯🇵
Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
🇯🇵Osaka University Hospital, Suita-shi, Japan
🇵🇱Przychodnia EuroMediCare Wroclaw Lowiecka, Wroclaw, Poland
TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 200
- Registration Number
- NCT04650828
- Locations
- 🇨🇳
Chaoshuang Lin, Guangzhou, China
HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.
- Conditions
- Liver Fibrosis
- Interventions
- Drug: PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 336
- Registration Number
- NCT04640129
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B
- Interventions
- Drug: PegIFN-alpha-2a (Optional)
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04585789
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇫🇷Hopital Beaujon, Clichy, France
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
- Conditions
- Hepatitis D, Chronic
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04535544
- Locations
- 🇯🇵
National Hospital Organization Shikoku Cancer Center, Iizuka-shi, Japan
🇺🇸Stanford University School of Medicine, Redwood City, California, United States
🇺🇸Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.